|Application ||E, IP|
|Host||Purified From HEK 293 Cell culture Supernatant.|
|Endotoxin||<0.01EU/ µg purified protein (LAL-test; Lonza)|
|Application Note||E,IP(1:200),Functional Applicational, Inhibits the binding of mouse APRIL to BCMA and TACI.|
|Calculated MW||26889 Da|
|Description||APRIL (mouse) monoclonal antibody (recombinant) (blocking) (APRY-1-1) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the mouse lgG2b Fc domain.|
|Other Names||A Proliferation Inducing Ligand; TNFSF13; CD256; TALL-2|
|Target/Specificity||Recognizes mouse APRIL. Does not recognize mouse BAFF.|
|Format||Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.|
|Reconstitution & Storage||Stable for at least 1 month after receipt when stored at +4°C. Stable for at least 1 year after receipt when stored at -20°C.|
|Precautions||Functional APRIL (mouse) Antibody, mAb (recombinant) (blocking) (Biotin) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
APRIL is a cytokine that belongs to the TNF superfamily and binds to TACI and BCMA. It is implicated in the regulation of tumor cell growth and is involved in monocyte/macrophage-mediated immunological processes.
Anti-APRIL (mouse) Monoclonal Antibody (recombinant) (Blocking) (APRY-1-1) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.